Here the authors report the results of a phase II trial to evaluate the diagnostic accuracy of an EGFR-targeted FMI for intraoperative margin assessment in patients with oral squamous cell carcinoma. The gene discussed is EGFR; the disease is oral cavity squamous cell carcinoma.